Clinical Trials Logo

Liposarcoma clinical trials

View clinical trials related to Liposarcoma.

Filter by:

NCT ID: NCT00233948 Terminated - Clinical trials for Recurrent Adult Soft Tissue Sarcoma

Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma

Start date: March 2006
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Antiviral drugs, such as nelfinavir mesylate, may help prevent cancer cells from spreading. PURPOSE: This phase I/II trial is studying the side effects and best dose of nelfinavir mesylate and to see how well it works in treating patients with recurrent, metastatic, or unresectable liposarcoma.

NCT ID: NCT00132704 Completed - Melanoma Clinical Trials

An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation

Start date: August 2004
Phase: Phase 3
Study type: Observational

Doctors will take some tissue from the tissue removed during surgery in order to study how the blood vessels of the tumor respond to radiation therapy. The tissue obtained will be used to determine how these tumor blood vessels respond to radiation therapy delivered to the tumor, after it has been removed. This radiation is delivered in the research lab. This research is being conducted in order to develop new methods to treat tumors by radiation therapy. No additional surgery will be performed to obtain these samples, and only materials that remain after all diagnostic testing has been completed will be used.

NCT ID: NCT00112463 Active, not recruiting - Clinical trials for Gastrointestinal Stromal Tumor

Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma

Start date: January 2004
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well depsipeptide (romidepsin) works in treating patients with metastatic or unresectable soft tissue sarcoma. Drugs used in chemotherapy, such as depsipeptide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

NCT ID: NCT00093080 Completed - Osteosarcoma Clinical Trials

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Start date: October 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the efficacy of ridaforolimus when administered once daily for 5 consecutive days (QDx5) every two weeks in participants with advanced sarcoma.

NCT ID: NCT00060944 Completed - Leiomyosarcoma Clinical Trials

A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer

Start date: May 2003
Phase: Phase 2
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.

NCT ID: NCT00004180 Completed - Sarcoma Clinical Trials

Rosiglitazone in Treating Patients With Liposarcoma

Start date: October 1999
Phase: Phase 2
Study type: Interventional

RATIONALE: Rosiglitazone may help liposarcoma cells develop into normal fat cells. PURPOSE: Phase II trial to study the effectiveness of rosiglitazone in treating patients who have liposarcoma.

NCT ID: NCT00003058 Completed - Sarcoma Clinical Trials

Troglitazone in Treating Patients With Liposarcoma

Start date: June 1997
Phase: Phase 2
Study type: Interventional

Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype.